CF
EBS icon

Centaurus Financial’s Emergent Biosolutions EBS Stock Holding History

Centaurus Financial’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,342
Closed -$135K – 858
2022
Q2 		$135K Buy
4,342
+546
+14% +$18.6K 0.01% 724
2022
Q1 		$156K Buy
3,796
+621
+20% +$27.4K 0.01% 738
2021
Q4 		$138K Hold
3,175
– – 0.01% 789
2021
Q3 		$159K Sell
3,175
-65
-2% -$3.94K 0.01% 717
2021
Q2 		$204K Sell
3,240
-6,130
-65% -$394K 0.02% 666
2021
Q1 		$871K Buy
+9,370
New +$960K 0.09% 259
2018
Q3 		– Sell
-2
Closed – – 915
2018
Q2 		$0 Buy
+2
New +$104 ﹤0.01% 2259

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Centaurus Financial's EBS Position: Q3 2022 in Review

Centaurus Financial sold out of Emergent Biosolutions (EBS) in Q3 2022, closing a stake of 4,342 shares — an estimated $135K sold.

Centaurus Financial first reported a position in EBS in Q2 2018 and held it in 7 quarters. The position peaked at $871K in Q1 2021. 211 funds tracked by Wall St. Rank hold EBS as of Q3 2022.

  • Centaurus Financial reported no remaining Emergent Biosolutions position as of Q3 2022 after selling out during the quarter.
  • Centaurus Financial sold 4,342 Emergent Biosolutions shares in Q3 2022, an estimated $135K.
  • Centaurus Financial first reported a position in Emergent Biosolutions in Q2 2018 and held it in 7 quarters.
  • Centaurus Financial's Emergent Biosolutions position peaked at $871K in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2022.

Based on Centaurus Financial's 13F filing for Q3 2022, filed 5 Dec 2022.